Stribild (emtricitabine tenofovir disoproxil cobicistat elvitegravir): Reviews and patient testimonials
Back to the list of medications
Medication indications
Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets
Stribild is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild (see sections 4.2, 4.4 and 5.1).
Stribild is also indicated for the treatment of HIV-1 infection in adolescents aged 12 to < 18 years weighing ≥ 35 kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate (TDF) (see sections 4.2, 4.4 and 5.1).
Route of administration: Oral
Molecule: emtricitabine, tenofovir disoproxil, cobicistat, elvitegravir
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.